Clinical trials: Osteopathia
Tuberculosis
A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in Brazil
This was a retrospective observational study that relied on data extracted from patient's chart review at the participating centers.
- Trial name
- ToBeReal (NCT06715254)
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis, Postmenopausal
Comparative Efficacy, Safety, PK, and Immunogenicity Study
this comparative clinical study is designed to demonstrate that LY06006 and EU-Prolia have no clinically meaningful differences in clinical efficacy, pharmacodynamic (PD), safety, PK, and immunogenicity in postmenopausal women…
- Trial name
- NCT05853354
- Testing
- Denosumab
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 392 people
- Sponsor
- Luye Pharma Group Ltd.
Osteoporosis
Study of FORTEO Use in Subjects in the Community Setting
The purpose of this study is to evaluate the long-term effectiveness, safety, and tolerability of FORTEO in a larger, more diverse "real world" population than studied in clinical trials
- Trial name
- DANCE (NCT01078805)
- Testing
- FORTEO
- Where
- United States
- Volunteers
- 4,167 people
- Sponsor
- Eli Lilly and Company
Osteoarthritis, Inflammatory Arthritis
Gender Solutions Natural Knee Post-Market Study
This is a prospective multicenter study of the Gender Solutions Natural Knee Flex System when used in primary total knee arthroplasty.
- Conditions
- Osteoarthritis, Inflammatory Arthritis, Post-traumatic Arthritis, Rheumatoid Arthritis
- Trial name
- NCT01463566
- Testing
- Zimmer Gender(R) Solutions(TM) Natural-Knee(R) Flex System
- Sponsor
- Zimmer Biomet
Acromegaly
Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.
The purpose of the protocol is to evaluate and describe QoL, in the population of Polish acromegalic patients treated with Lanreotide Autogel® 120 mg during the 24 months (long term observation).
- Trial name
- ACRO QLQ (NCT02396966)
- Where
- 18 sites in Poland
- Volunteers
- 152 people
- Sponsor
- Ipsen
Psoriatic Arthritis
A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis
The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drugs (DMARD) naive.
- Trial name
- SPIRIT-H2H (NCT03151551)
- Testing
- Ixekizumab, Adalimumab
- Where
- 131 sites in Argentina, Australia and 20 more
- Volunteers
- 566 people
- Sponsor
- Eli Lilly and Company
Postmenopausal Osteoporosis
Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers
CMAB807 is a human monoclonal antibody targeting the key bone resorption mediator RANKL. The drug is administered via subcutaneous injection once six months and is approved for various indications, including the treatment of…
- Trial name
- NCT03925051
- Testing
- Prolia®, CMAB807
- Where
- China
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Shanghai Biomabs Pharmaceutical Co., Ltd.
Ankylosing Spondylitis
Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis
This study assessed the clinical Assessment of SpondyloArthritis international Society (ASAS) 20 response to secukinumab and evaluated to which extent concomitant nonsteroidal anti-inflammatory drug (NSAID) treatment can be…
- Trial name
- ASTRUM (NCT02763046)
- Testing
- Secukinumab (AIN457) 150 mg s.c.
- Where
- 39 sites in Germany
- Volunteers
- 211 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma, Anaplastic Astrocytoma
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
In this multinational dose finding Phase IIb study the efficacy and safety of two doses of AP 12009 compared to standard chemotherapy (temozolomide or PCV) is investigated in adult patients with confirmed recurrent high-grade…
- Trial name
- NCT00431561
- Testing
- AP 12009 10 µM, AP 12009 80 µM, temozolomide or PCV
- Where
- 36 sites in Austria, Georgia and 4 more
- Volunteers
- 141 people
- Sponsor
- Isarna Therapeutics GmbH
Joint Disease
Post Market Clinical Follow-Up Study Protocol for PROCOTYL® C Acetabular Components
MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) components marketed in the European Union (EU).
- Trial name
- NCT03576573
- Testing
- PROCOTYL® C
- Where
- Germany
- Volunteers
- 143 people
- Sponsor
- MicroPort Orthopedics Inc.
Osteoporosis
FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267)
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of FOSAMAX PLUS / FOSAMAX PLUS…
- Trial name
- NCT01065779
- Testing
- FOSAMAX PLUS, FOSAMAX PLUS D
- Volunteers
- 880 people
- Sponsor
- Organon and Co
Acromegaly
Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors…
- Trial name
- NCT00658879
- Testing
- Somavert (Pegvisomant)
- Volunteers
- 251 people
- Sponsor
- Pfizer
Osteoporosis
Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose Evaluation
To establish the optimal dose of lasofoxifene that is fully effective in increasing the BMD in postmenopausal Asian women.
- Trial name
- JADE (NCT00143273)
- Testing
- lasofoxifene
- Where
- 17 sites in Japan, South Korea and 1 more
- Volunteers
- 497 people
- Sponsor
- Ligand Pharmaceuticals
Osteoporosis
Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031)
This study will evaluate the safety and treatment effect of 50 mg odanacatib (MK-0822) with Vitamin D versus placebo with Vitamin D in postmenopausal women with low bone density.
- Trial name
- NCT00729183
- Testing
- Odanacatib, Vitamin D3, Calcium supplement
- Volunteers
- 214 people
- Sponsor
- Merck Sharp & Dohme LLC
Joint Diseases, Osteoarthritis
Post Market Clinical Follow-Up Study for EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert
MicroPort Orthopedics Inc. (MPO) plans to market the EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® NitrX™ CS/CR Non-Porous Femur with the EVOLUTION® Cruciate Sacrificing (CS) Tibial Insert globally, including in the…
- Conditions
- Joint Diseases, Osteoarthritis, Arthritis Knee, Avascular Necrosis
- Trial name
- NCT04816773
- Testing
- EVOLUTION® NitrX™
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 150 people
- Sponsor
- MicroPort Orthopedics Inc.
Rheumatoid Arthritis, Osteoarthritis
G7 BiSpherical Acetabular Shell PMCF Study
The primary objective of this study is to obtain implant survivorship and clinical outcomes data for the commercially available G7 BiSpherical Acetabular Shell.
- Conditions
- Rheumatoid Arthritis, Osteoarthritis, Noninflammatory Degenerative Joint Disease, Avascular Necrosis
- Trial name
- NCT03266874
- Where
- 5 sites in France, Germany and 2 more
- Volunteers
- 160 people
- Sponsor
- Zimmer Biomet
Degenerative Disc Disease
Adipose Cells for Degenerative Disc Disease
The intent of this clinical study is to answer the questions: 1) Is the proposed treatment safe and 2) Is treatment effective in improving the disease pathology of patients with diagnosed degenerative disc disease.
- Trial name
- NCT02097862
- Testing
- Adipose Stem Cells
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Bioheart, Inc.
Breast Cancer, Low Bone Mineral Density
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer
The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.
- Conditions
- Breast Cancer, Low Bone Mineral Density, Osteopenia
- Trial name
- NCT00089661
- Testing
- AMG 162 / Denosumab
- Volunteers
- 252 people
- Sponsor
- Amgen
Degenerative Disc Disease
Osteocel® Plus in Posterior Lumbar Interbody Fusion (PLIF)
This study is being conducted to determine the percentage of patients with solid spinal fusions after being treated with Osteocel Plus in a PLIF procedure.
- Trial name
- NCT00941980
- Testing
- Osteocel Plus
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- NuVasive
Osteoporosis, Postmenopausal
Generic Zoledronic Acid Versus Original Zoledronic Acid in Postmenopausal Osteoporotic Women
This study compares the efficacy and safety of generic zoledronic acid (Yigu®) and original zoledronic acid (Aclasta®) in the treatment of postmenopausal osteoporotic women in China.
- Trial name
- NCT03158246
- Testing
- Generic Zoledronic Acid, Original Zoledronic Acid, calcium
- Volunteers
- 466 people
- Sponsor
- Cttq
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.